Sanofi will not be pursuing approval of tolebrutinib for PPMS, and an FDA decision on the therapy in nonrelapsing SPMS will ...
The milestone marks the next phase of the company’s initiative to scale market-ready artificial intelligence solutions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback